





Contract Research & Provision

F-PDO®

Japanese Patient-derived Tumor Organoids



Lung F-PDO (squamous cell carcinoma)



Lung F-PDO (papillary adenocarcinoma)

F-PDOs * have retained the characteristics of tumor tissues during long period of *in vitro* culture, which have been confirmed by

- ➔ Comprehensive gene expression analysis
- ➔ Genomic analysis
- ➔ Histological analysis

* Patient-derived tumor organoids established in Fukushima project

Applications


- *In vitro* high-throughput assay of anticancer agents
- Study of cancer cell biology
- Biomarker development
- Xenograft models using F-PDO

F-PDO® lines

| | |
|--------------------|----|
| Lung cancer | 21 |
| Endometrial cancer | 20 |
| Ovarian cancer | 15 |
| Sarcoma | 6 |
| Colorectal cancer | 4 |
| Breast cancer | 3 |
| Peritoneal cancer | 4 |
| Brain cancer | 2 |
| Cervical cancer | 2 |
| Bile duct cancer | 1 |
| Gastric cancer | 1 |
| Leukemia via PDX | 3 |



Lung cancer



Endometrial cancer




Ovarian cancer


Total: **82** lines



Lung cancer



Endometrial cancer



Ovarian cancer

F-PDO is a registered trademark of Public University Corporation FUKUSHIMA MEDICAL UNIVERSITY.

✉ Contact information 

Summit Pharmaceuticals International

For purchase orders and inquiries regarding F-PDO®/F-PDX® products and the related service, please contact Summit Pharmaceuticals International Co. who is the official distributor.

 **Website** <http://www.summitpharma.co.jp/english/index.html>

